Scheduling Agreement Sample Clauses

Scheduling Agreement. Part A of the Schedule to the Tax Information Exchange Act (No. 21 of 2010) is amended by inserting the following information:
Sample 1Sample 2Sample 3See All (10)
AutoNDA by SimpleDocs
Scheduling Agreement. The following Scheduling Rules were agreed to by both parties in Bargaining 2013, and will be implemented for all Cashiers, General Clerks, Bakery Clerks, Service Clerks, Coffee Bar Servers, Pharmacy Assistants and Registered Pharmacy Technicians: 1. Seniority date to be included by employee name on the schedule. 2. Clearly delineate between Grid A, Grid B Daily and Grid B Weekly Seniority. 3. Weekly hours restrictions will be identified on the schedule beside the employee’s name. 4. Students as well as employees who are restricted to 24 hours or less per week and who have submitted a Declaration of Availability will have their time of day/day of week availability shown on the schedule. Sunday and Weekday Restrictions shall also be noted on the schedule. 5. Proper acronyms will be used on the schedule to show why an employee does not have shift. Eg., TAB, RTO, ATO. 6. Management in all departments (including Clerk(s)-In-Charge, Assistant Department Managers) will be identified on the schedule. Note that Assistant Coffee Bar Operators are not key personnel. 7. Clerk(s)-In-Charge and Assistant Department Managers will be scheduled by his/her company seniority date. 8. Employees must be scheduled in correct classification even if working another classification (this applies to employees hired prior to ratification 2013 who are on the transfer program). 9. There shall be no handwritten schedules. 10. All General Clerks to be included on a single work schedule. 11. No reprinting of current week’s schedule. Changes made after the schedule is posted are to be written on the schedule and initialed by management or designate. 12. Current week’s sickness and call-ins to be indicated on schedule, and initialed by management or designate. 13. Failure to comply with scheduling obligations set forth in this agreement will result in a written warning. Thereafter, subsequent violations in the same store will be met with increasing fines payable to UFCW 1518 set forth below: Second Violation: $25 Third Violation: $50 Forth Violation: $100 Fifth and Subsequent Violations: $200 Where no violation occurs in the same store for a period of twelve (12) months following a written warning or from the date of the last fine, the process begins again starting with a written warning, followed by second, third and fourth, fifth and subsequent violations as noted above. The Union will enforce the fine system reasonably. 14. The parties reserve the right to meet to discuss any anomalies ...
Sample 1Sample 2Sample 3See All (7)
Scheduling Agreement. Delivery Based on Call-offs
Sample 1Sample 2See All (4)
Scheduling Agreement. Within 90 days after receipt of notice under subsection (a), the Secretary of the Interior, the Secretary of Commerce, the Administrator of the Environmental Protection Agency, and any State or local agencies that have notified the Secretary under subsection (b) shall enter into an agreement with the Secretary establishing a schedule of decisionmaking for approval of the project and permits associated with it and with related activities. Such schedule may not exceed two and one-half years from the date of the agreement.
Sample 1Sample 2
Scheduling Agreement. In order for CBHS staff to schedule you in a timely manner and allow for timely follow-up appointments, it is your responsibility to communicate when you are unable to keep your appointment not only as a courtesyto your provider and other patients, but also for administrative purposes as our staff prepares for each and every patient visit. Please be advised that 3 no shows for any provider will result in discharge from the practice. 24 hour notice must be provided to cancel an appointment or a no show fee of $35.00 will be charged to your account and you may not be able to reschedule the missed appointment for 60 days. Saturday appointment no show fee rate is $100 and you will not be able to schedule another Saturday appointment for 6 months.
Sample 1
Scheduling Agreement. THE UNDERSIGNED AGREES TO MAKE EVERY EFFORT TO KEEP SCHEDULED APPOINTMENTS AND ARRIVE 10-15 MINUTES EARLY. APPOINTMENTS THAT CANNOT BE KEPT SHOULD BE CANCELLED 24 HOURS IN ADVANCE. APPOINTMENTS THAT ARE NOT CANCELLED AT LEAST 24 HOURS PRIOR TO THE SCHEDULED TIME WILL BE SUBJECT TO A NO SHOW FEE OF $50.00 TO $100.00 DEPENDING ON THE LENGTH OF THE APPOINTMENT. PATIENTS THAT ARRIVE 15 MINUTES OR LATER FOR A SCHEDULED APPOINTMENT WILL BE ASKED TO RESCHEDULE, AND MAY ALSO BE SUBJECT TO A NO SHOW FEE, TO BE DETERMINED ON A CASE-BY-CASE BASIS. PATIENTS THAT NO SHOW 3 OR MORE SCHEDULED APPOINTMENTS IN 1 YEAR, WITHOUT CALLING TO CANCEL THE APPOINTMENT, WILL BE REVIEWED AND MAY BE RELEASED FROM THE PRACTICE.
Sample 1

Related to Scheduling Agreement

  • Interconnection Agreement Seller shall comply with the terms and conditions of the Interconnection Agreement.

  • Transitional Services Agreement Seller shall have executed and delivered the Transitional Services Agreement.

  • Services Agreement “Services Agreement” shall mean any present or future agreements, either written or oral, between Covered Entity and Business Associate under which Business Associate provides services to Covered Entity which involve the use or disclosure of Protected Health Information. The Services Agreement is amended by and incorporates the terms of this BA Agreement.

  • Master Services Agreement This Agreement is a master agreement governing the relationship between the Parties solely with regard to State Street’s provision of Services to each BTC Recipient under the applicable Service Modules.

  • Transition Services Agreement Seller shall have executed and delivered the Transition Services Agreement.

  • Controlling Agreement To the extent the terms of this Agreement (as amended, supplemented, restated or otherwise modified from time to time) directly conflicts with a provision in the Merger Agreement, the terms of this Agreement shall control.

  • Cooperation Agreement If a Cooperating Institution is appointed, the Fund shall enter into a Cooperation Agreement with the Cooperating Institution setting forth the terms and conditions of its appointment.

  • Data Processing Agreement The Data Processing Agreement, including the Approved Data Transfer Mechanisms (as defined in the Data Processing Agreement) that apply to your use of the Services and transfer of Personal Data, is incorporated into this Agreement by this reference. Each party will comply with the terms of the Data Processing Agreement and will train its employees on DP Law.

  • Transition Agreement In the event of termination of this Agreement in its entirety by AbbVie pursuant to Section 12.3.2 or by Galapagos pursuant to Section 12.2.1, or with respect to one (1) or more countries or other jurisdictions by AbbVie pursuant to Section 12.3 or by Galapagos pursuant to Section 12.2.2(i), Galapagos and AbbVie shall negotiate in good faith the terms and conditions of a written transition agreement (the “Transition Agreement”) pursuant to which AbbVie and Galapagos will effectuate and coordinate a smooth and efficient transition of relevant obligations and rights to Galapagos as reasonably necessary for Galapagos to exercise the licenses granted pursuant to Sections 12.6 or 12.7 after termination of this Agreement (in its entirety or with respect to one (1) or more countries or other jurisdictions, as applicable) as and to the extent set forth in this Article 12. For clarity, AbbVie shall not be required to Manufacture or have Manufactured the Molecules or Products by or on behalf of Galapagos as part of the Transition Agreement. 12.8.1 The Transition Agreement shall provide that in the event of a termination of this Agreement in its entirety by AbbVie pursuant to Section 12.3.2 or by Galapagos in its entirety pursuant to Section 12.2.1, AbbVie shall: (i) where permitted by Applicable Law, transfer to Galapagos all of its right, title, and interest in all Regulatory Documentation then Controlled by AbbVie or its Affiliates or Sublicensees and in its/their name applicable to the Products in the Territory that are the subject of an exclusive license grant in Section 12.6.1(iii); (ii) notify the applicable Regulatory Authorities and take any other action reasonably necessary to effect the transfer set forth in clause (i) above; (iii) if requested by Galapagos and unless expressly prohibited by any Regulatory Authority, transfer control to Galapagos of all Clinical Studies being Conducted by AbbVie or its Affiliates or Sublicensees as of the effective date of termination and continue to Conduct such Clinical Studies, at Galapagos’ cost, for up to […***…] ([…***…]) months to enable such transfer to be completed without interruption of any such Clinical Study; provided, that (a) Galapagos shall not have any obligation to continue any Clinical Study unless required by Applicable Law, and (b) with respect to each Clinical Study for which such transfer is expressly prohibited by the applicable Regulatory Authority, if any, AbbVie shall continue to Conduct such Clinical Study to completion, at Galapagos’ cost; and (iv) assign (or cause its Affiliates or Sublicensees to assign) to Galapagos all agreements with any Third Party with respect to the Conduct of pre-clinical Development activities, Clinical Studies or Manufacturing activities for the Products, including agreements with contract research organizations, clinical sites, and investigators, unless, with respect to any such agreement, (a) Galapagos declines such assignment, or (b) such agreement (1) expressly prohibits such assignment, in which case AbbVie shall cooperate with Galapagos in reasonable respects to secure the consent of the applicable Third Party to such assignment, or (2) covers products covered by Patents Controlled by AbbVie or any of its Affiliates in addition to the Products, in which case AbbVie shall, at Galapagos’ sole cost and expense, cooperate with Galapagos in all reasonable respects to facilitate the execution of a new agreement between Galapagos and the applicable Third Party. 12.8.2 The Transition Agreement shall provide that in the event of a termination of this Agreement with respect to a country or other jurisdiction by AbbVie pursuant to Section 12.3 or by Galapagos pursuant to Section 12.2.2(i) (but not in the case of any termination of this Agreement in its entirety), AbbVie shall: (i) where permitted by Applicable Law, transfer to Galapagos all of its right, title, and interest in all Regulatory Approvals owned by, or in the name of, AbbVie or its Affiliates or Sublicensees, which Regulatory Approvals are solely applicable to the relevant country or jurisdiction and the Products that are the subject of an exclusive license grant in Section 12.7, as such Regulatory Approvals exists as of the effective date of such termination of this Agreement with respect to such relevant country or jurisdiction; provided, that AbbVie retains a license and right of reference under any Regulatory Approval transferred pursuant to this clause as necessary or reasonably useful for AbbVie to Commercialize Products in the Territory, Develop Molecules or Products in support of such Commercialization, or Manufacture Molecules or Products in support of such Development or Commercialization; (ii) notify the applicable Regulatory Authorities and take any other action reasonably necessary to effect the transfer set forth in clause (i) above; (iii) grant Galapagos a right of reference to all Regulatory Documentation then owned by, or in the name of, AbbVie or its Affiliates or Sublicensees, and which Regulatory Documentation is not transferred to Galapagos pursuant to clause (i) above, and is necessary or reasonably useful for Galapagos, any of its Affiliates or sublicensees to Develop or Commercialize in the terminated country or jurisdiction the Product(s) that are the subject of the license grant in Section 12.7 as such Regulatory Documentation exists as of the effective date of such termination of this Agreement with respect to such terminated country or jurisdiction; (iv) if requested by Galapagos and unless expressly prohibited by any Regulatory Authority, transfer control to Galapagos of all Clinical Studies specific to such terminated country(ies) being Conducted by AbbVie or its Affiliates or Sublicensees as of the effective date of termination and continue to Conduct such Clinical Studies, at Galapagos’ cost, for up to […***…] ([…***…]) months to enable such transfer to be completed without interruption of any such Clinical Study; provided, that (a) Galapagos shall not have any obligation to continue any Clinical Study unless required by Applicable Law, and (b) with respect to each Clinical Study for which such transfer is expressly prohibited by the applicable Regulatory Authority, if any, AbbVie shall continue to Conduct such Clinical Study to completion, at Galapagos’ cost; and (v) assign (or cause its Affiliates or Sublicensees to assign) to Galapagos all agreements with any Third Party with respect to the Conduct of Clinical Studies specific to such terminated country(ies), including agreements with contract research organizations, clinical sites, and investigators, unless, with respect to any such agreement, (a) Galapagos declines such assignment, or (b) such agreement (1) expressly prohibits such assignment, in which case AbbVie shall cooperate with Galapagos in reasonable respects to secure the consent of the applicable Third Party to such assignment, or (2) covers products covered by Patents Controlled by AbbVie or any of its Affiliates in addition to the Products, in which case AbbVie shall, at Galapagos’ sole cost and expense, cooperate with Galapagos in all reasonable respects to facilitate the execution of a new agreement between Galapagos and the applicable Third Party.

  • Service Agreement Refers to the Contract, Purchase Order or Terms of Service or Terms of Use. Student Data: Student Data includes any data, whether gathered by Provider or provided by LEA or its users, students, or students’ parents/guardians, that is descriptive of the student including, but not limited to,

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!